⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTNM News
Contineum Therapeutics, Inc. Class A Common Stock
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
businesswire.com
CTNM
Form 8-K
sec.gov
CTNM
Form 8-K
sec.gov
CTNM
Form 8-K
sec.gov
CTNM
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
businesswire.com
CTNM
Form 8-K
sec.gov
CTNM
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
businesswire.com
CTNM
Form 8-K
sec.gov
CTNM
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM